证券代码：688139 证券简称：海尔生物 公告编号：2025-044 青岛海尔生物医疗股份有限公司 | | | 1 | 2019年10月22日实际到账的募集资金 | 1,161,576,074.14 | | --- | --- | | 减：支付的其他发行费用 | 4,670,375.54 | | 募集资金净额 | 1,156,905,698.60 | | 减：募投项目支出金额 | 1,029,056,832.19 | | 其中：以前年度累计使用的募集资金 | 988,378,129.28 | | 本年度投入募投项目支出 | 40,678,702.91 | | 减：永久补充流动资金 | 124,550,000.00 | | 减：期末用于现金管理的暂时闲置募集资金金额 | 87,840,000.00 | | 加：募集资金现金管理产品累计收益金额 | 72,784,401.15 | | 加：累计利息收入扣除手续费金额 | 11,808,991.14 | | 截至2025年6月30日募集资金余额 | 52,258.70 | 2025 年半年度募集资金存放与使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在 ...

青岛海尔生物医疗股份有限公司 关于公司 2025 年度"提质增效重回报"专项行动方案的 青岛海尔生物医疗股份有限公司（以下简称"公司"、"海尔生物"）为践行 "以投资者为本"的上市公司发展理念，维护公司全体股东利益，增强投资者信 心，促进公司长远健康可持续发展，基于对公司未来发展前景的信心和对公司价 值的认可，已连续两年发布"提质增效重回报"专项行动方案。根据 2025 年 3 月 29 日发布的《海尔生物"提质增效重回报"2024 年度评估报告暨 2025 年度 行动方案》，报告期内公司积极开展和落实各项工作，现将 2025 年上半年的主要 工作成果报告如下： 一、 加快发展新质生产力，聚焦四大产业，夯实全球市场竞争力 在人工智能底座深度融合的基础上，报告期内四横四纵平台加强联动，驱 动研发效率提升、技术成果产出加快和产品创新提速。上半年公司研发投入 1.60 亿元，占营业收入的比重为 13.39%；公司新品研发周期同比缩短 6%，发明专利 累计获得数同比增长 48%，累计 32 项成果被鉴定为国际领先水平成果，牵头或 参与起草国家/行业/地方团体等标准 64 项，获得省级以上科技奖励 45 项，上半 年荣 ...

海尔生物公告，2025年上半年营业收入11.96亿元，同比下降2.27%。归属于上市公司股东的净利润1.43 亿元，同比下降39.09%。基本每股收益0.45元／股，同比减少39.19%。 ...

Core Viewpoint - Haier Biomedical is a service provider for life sciences and medical innovation digital solutions, focusing on low-temperature storage, laboratory solutions, smart medication, and blood technology, with products covering over 150 countries and regions [1] Group 1: Stock Performance - As of August 20, 2025, Haier Biomedical's stock price closed at 34.91 yuan, down 0.09 yuan, a decrease of 0.26% from the previous trading day [1] - The trading volume on that day was 41,111 hands, with a transaction amount of 1.42 billion yuan [1] Group 2: Strategic Partnerships - On August 19, 2025, Haier Biomedical signed a strategic cooperation agreement with Thailand's RAM Medical Group, focusing on pharmacy automation and smart healthcare solutions [1] - RAM Medical Group is the second-largest private hospital group in Thailand, operating 50 hospitals [1] - The agreement includes a pilot project for pharmacy automation solutions, covering outpatient pharmacy automation systems and intelligent inventory management modules [1] Group 3: Financial Updates - Haier Biomedical announced it will hold a semi-annual performance briefing on August 28, 2025 [1] - On August 20, 2025, the net inflow of main funds into Haier Biomedical was 389,900 yuan, with a cumulative net inflow of 1.65 million yuan over the past five days [1]

强强联合：精准锚定东南亚医疗升级刚需 本报讯(记者刘钊)在全球贸易自由化纵深推进与医疗新基建加速落地的双重浪潮下，中国医疗科技企业 正以技术创新与本土化深耕并重的姿态，在全球市场书写"中国方案"。8月19日，盈康一生旗下青岛海 尔生物医疗股份有限公司(以下简称"海尔生物")与泰国三大私立医院集团之一的RAM医疗集团 (Ramkhamhaeng HospitalGroup)签署战略合作协议，双方将在药房自动化、智慧医疗全场景等领域展开 深度协同。 这场"技术方案+本土服务"的联合，不仅标志着海尔生物"一国一策"海外战略在东南亚市场再结硕果， 更成为其从"产品输出"向"生态共建"探索的关键一步。 在产品端，海尔生物以深度本土化为核心，针对东南亚市场的气候特征、医疗流程、政策标准定制解决 方案。例如，针对热带地区药品存储需求优化的智能冷链系统，适配私立医院网络的分布式库存管理模 块，均体现了"精准画像、按需定制"的战略思路。在运营端，通过建立覆盖营销、物流、售后的本地化 运营中心，海尔生物已实现从"卖产品"到"做服务"的转型，此次与RAM医疗集团共建合作基地，更将 形成"实地演示+经验共享"的区域辐射机制——未来该 ...

Core Viewpoint - The collaboration between Haier Biomedical and RAM Medical Group marks a significant step in China's medical technology companies' global expansion, focusing on technology innovation and localized services in Southeast Asia [1][3]. Group 1: Strategic Collaboration - Haier Biomedical signed a strategic cooperation agreement with RAM Medical Group, one of Thailand's major private hospital groups, to enhance automation in pharmacies and smart healthcare solutions [1][3]. - The partnership aims to implement pharmacy automation solutions, including outpatient pharmacy automation systems and smart inventory management modules, to improve efficiency and safety in medical services [4][5]. Group 2: Market Potential in Southeast Asia - Southeast Asia, with a population of 670 million and over 10% elderly population growth, is becoming a key market for medical industry expansion [3]. - Thailand, as a regional medical hub, has a pressing need for upgrades in pharmacy automation and smart medical devices, providing a strategic entry point for Chinese medical technology companies [3][4]. Group 3: Customized Solutions and Local Operations - Haier Biomedical focuses on customized solutions tailored to the Southeast Asian market, addressing local climate, medical processes, and policy standards [4][5]. - The company has established localized operational centers covering marketing, logistics, and after-sales services, transitioning from a product-selling model to a service-oriented approach [5][6]. Group 4: Broader Implications for Chinese Medical Technology - The collaboration is seen as a model for the upgrade of the Southeast Asian medical industry, showcasing a shift from cost-based competition to value-driven innovation [6]. - Haier Biomedical's approach emphasizes technology-driven standards and patient experience, positioning Chinese medical technology as a leader rather than a follower in the global market [6].

Core Insights - The collaboration between Haier Biomedical and RAM Medical Group marks a significant step in Haier's "one country, one policy" overseas strategy, focusing on technology solutions and localized services in Southeast Asia [1][5][6] - Southeast Asia, with its growing elderly population and economic development, presents a lucrative market for medical technology, particularly in Thailand, which has urgent needs for automation and smart medical devices [3][5] Group 1: Strategic Collaboration - Haier Biomedical has signed a strategic cooperation agreement with RAM Medical Group to implement pharmacy automation and smart medical solutions, enhancing healthcare efficiency and safety [4][6] - The partnership aims to create a comprehensive ecosystem by integrating customized products and localized operations, transitioning from merely selling products to providing services [5][6] Group 2: Market Potential - Southeast Asia's population of 670 million and over 10% growth in the elderly demographic make it a prime market for medical technology advancements [3][7] - The collaboration is expected to serve not only local Thai patients but also international medical tourists, thereby injecting efficiency and safety into regional healthcare services [4][6] Group 3: Technological Innovation - Haier Biomedical's approach emphasizes "customized technology + localized operations" to address the diverse needs of different medical markets, showcasing its capabilities in low-temperature storage and laboratory solutions [3][5] - The partnership will initially focus on pharmacy automation solutions, including outpatient pharmacy systems and smart inventory management, to streamline the drug distribution process [4][6] Group 4: Future Outlook - The collaboration is seen as a model for replicating successful strategies in other emerging markets, potentially expanding Haier Biomedical's influence in the global healthcare landscape [6][7] - As the partnership develops, RAM Medical Group plans to gradually adopt a full range of Haier Biomedical's products and solutions, indicating a shift from isolated projects to a comprehensive healthcare ecosystem [5][6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688139 证券简称：海尔生物 公告编号：2025-042 青岛海尔生物医疗股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025年08月28日(星期四)下午13:00-14:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2025年08月21日（星期四）至08月27日（星期三）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱haierbiomedical@haierbiomedical.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）将于2025年8月27日发布公司2025年半年度报告， 为便于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于 ...

证券日报网讯 8月19日晚间，海尔生物发布公告称，公司将于2025年8月28日召开2025年半年度业绩说 明会。 （文章来源：证券日报） ...

Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical and biological enterprises, research institutions, hospitals, and public health organizations [2] - The company has developed two main business segments: life sciences and medical innovation, offering comprehensive digital solutions such as smart laboratories and digital hospitals [2] Product Portfolio - Major products include low-temperature storage boxes, automated biological sample storage systems, fully automated cell culture workstations, and various medical automation products [2] - The company has received multiple awards and certifications, enhancing its innovation capabilities in life sciences and medical fields [2] Financial Performance - For Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a decrease of 19.88% [3] - The gross profit margin stands at 48.35% [3] Market Position - As of August 19, the company's stock closed at 35.0 yuan, with a rolling PE ratio of 32.80 times, and a total market capitalization of 11.128 billion yuan [1] - The average PE ratio in the medical device industry is 59.49 times, with a median of 40.19 times, placing the company at the 64th position in the industry ranking [1][3] Institutional Holdings - As of Q1 2025, there is one institutional holder of the company, with a total holding of 430,200 shares valued at 1.3 million yuan [1]